10 studies found for:    Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego
Show Display Options
Rank Status Study
1 Recruiting Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
Conditions: Coronary Artery Disease;   Coronary Disease;   Myocardial Ischemia;   Heart Diseases;   Cardiovascular Diseases;   Arteriosclerosis;   Arterial Occlusive Diseases;   Vascular Diseases
Intervention: Procedure: CorPath-assisted Percutaneous Coronary Intervention
2 Recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
Intervention:
3 Recruiting Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Condition: Abdominal Aortic Aneurysm (AAA)
Intervention: Device: Nellix System
4 Recruiting Single Dose Enteral Tranexamic Acid in Critically Ill Patients
Conditions: Shock;   Sepsis;   Hypotension;   Critical Illness
Intervention: Drug: Tranexamic Acid
5 Recruiting Evaluation of the Duration of Therapy for Thrombosis in Children
Condition: Venous Thrombosis
Interventions: Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention;   Drug: Dalteparin
6 Recruiting Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Condition: Portopulmonary Hypertension
Intervention: Drug: Ambrisentan
7 Recruiting Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone;   Drug: Velcade plus dexamethasone
8 Unknown  Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) Patients
Conditions: Chronic Thromboembolic Pulmonary Hypertension;   Acute Lung Injury
Intervention: Other: Ventilation Strategy
9 Recruiting SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
10 Recruiting Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Conditions: B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292

Indicates status has not been verified in more than two years